Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow PALVELLA THERAPEUTICS, INC.

Get SEC filing alerts via email and in your feed for PALVELLA THERAPEUTICS, INC.

PVLA

PALVELLA THERAPEUTICS, INC.

About PALVELLA THERAPEUTICS, INC.

Palvella Therapeutics develops topical, targeted therapies for serious, rare genetic skin diseases. Its lead product, QTORIN rapamycin, aims to treat microcystic lymphatic malformations and venous malformations by delivering rapamycin directly to affected skin layers, minimizing systemic side effects. The company leverages its proprietary QTORIN platform, focusing on unmet medical needs, innovative formulations, and strategic collaborations to become a leader in rare dermatologic conditions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from PALVELLA THERAPEUTICS, INC.

1
1
PALVELLA THERAPEUTICS, INC. Palvella Therapeutics Reports $15.8M Net Loss and $206.4M Cash Reserves in Latest 10-Q

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
PALVELLA THERAPEUTICS, INC. Palvella Therapeutics Completes Merger and Reports Positive Clinical Trial Results for QTORIN Rapamycin

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
PALVELLA THERAPEUTICS, INC. Palvella Therapeutics Reports $11.3 Million Net Loss in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
PALVELLA THERAPEUTICS, INC. Palvella Therapeutics Reports $9.5 Million Net Loss in Q2 2025 Amid Increased R&D Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
PALVELLA THERAPEUTICS, INC. Palvella Therapeutics Reports Increased Operating Expenses and Net Losses in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
PALVELLA THERAPEUTICS, INC. Palvella Therapeutics Reports $17.4 Million Net Loss for 2024 Following Business Combination

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
PALVELLA THERAPEUTICS, INC. Pieris Pharmaceuticals Reports Significant Financial Changes in 10-Q Filing, Including Revenue Decline and Improved Net Loss

Via official filing (AI summary) | over 1 year ago | 0 comments